Literature DB >> 6145299

Calcium influx blockers in the treatment of essential hypertension.

U L Hulthén, P Bolli, F R Bühler.   

Abstract

Elevated vascular resistance is the key factor in most cases of essential hypertension. Vascular resistance is determined by the sarcoplasmatic concentration of free Ca2+. Experimental studies have shown an increased dependence for the noradrenaline-induced contraction on extracellular Ca2+ from the aorta to the small resistance vessels. This is in accordance with the potent vasodilating effect found with Ca2+-influx inhibitors in man. Furthermore, a selective enhancement of the vasodilating response to verapamil has been found in patients with essential hypertension as compared to normotensive subjects. The verapamil-induced vasodilation in the hypertensive patients was positively correlated to plasma adrenaline concentration. These findings suggest accentuated Ca2+-influx dependent vasoconstriction in essential hypertension, which is related to the activity of the sympathetic nervous system. Acute administration of verapamil and nifedipine results in a distinct fall in blood pressure in patients with essential hypertension but not in normotensive subjects. Generally, the percentage fall in blood pressure with Ca2+-channel blockers has been closely positively correlated to the initial blood pressure level and in an open study with 43 patients with essential hypertension the decrease in blood pressure to verapamil was also positively correlated to the age of patients. These data may provide the basis for a new treatment concept for essential hypertension proposing a Ca2+-channel blocker as the first choice for the older patients and a beta-adrenoceptor blocking agent as the first line drug for the younger patients. Combined treatment with a beta-adrenoceptor blocking agent and a Ca2+-channel blocker seems most efficient in normalizing blood pressure in many therapy-resistant hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145299     DOI: 10.1111/j.0954-6820.1984.tb08683.x

Source DB:  PubMed          Journal:  Acta Med Scand Suppl        ISSN: 0365-463X


  5 in total

Review 1.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 2.  Studies on verapamil in the treatment of essential hypertension: a review.

Authors:  K Midtbø; O Hals; O Lauve; J van der Meer; L Storstein
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 3.  Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  A Fitton; P Benfield
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

4.  Metabolic parameters after changing from hydrochlorothiazide to verapamil treatment in hypertension.

Authors:  A Lehtonen; A Gordin
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Comparison of the efficacy of nicardipine, a new calcium channel blocker, with nifedipine in the treatment of mild to moderate essential hypertension.

Authors:  C Armstrong; J Garnham; R Blackwood
Journal:  Postgrad Med J       Date:  1987-06       Impact factor: 2.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.